Click for best price
Postpemic Era NonInvasive Cancer Diagnostics Market Size, Share 2022
Summary
The global and Chinese economies were hit hard in 2020, and the global GDP grew by 5.9% in 2021. Although the global growth prospects improved and there was a V-shaped rebound, this does not mean that the economy has really recovered to the level before the epidemic. The vast majority of countries are still in the stage of recovery after heavy damage and are far from achieving real recovery.
2022 is a year of continuous recovery. Global supply chain disturbance, geopolitical tension, energy price fluctuation, local labor shortage and rising raw material prices will affect the resilience of economic recovery. The International Monetary Fund (IMF) predicts that the world economy will grow by 4.4% in 2022, of which the U.S. economy will grow by about 4%. Driven by China and India, Asia is expected to become the fastest growing region in the world in 2022. However, China's economic growth has slowed down. The 2022 government work report shows that the expected target of economic growth is set at about 5.5%.
According to research, China has set a growth rate of about 5.5%, which not only focuses on the speed of economic growth, but also anchors the quality of economic development. Scientific and technological innovation, economic and social digitization and green development will be the long-term goals of China's economic development. It is expected that in 2022, major economies such as the United States, Europe and China will introduce more favorable policies to drive the development of switching power supply industry.
Global Non-Invasive Cancer Diagnostics Market Segment Research Report 2022?, which aims to sort out the development status and trends of the Non-Invasive Cancer Diagnostics industry at home and abroad, estimate the overall market scale of the Non-Invasive Cancer Diagnostics industry and the market share of major countries, Non-Invasive Cancer Diagnostics industry, and study and judge the downstream market demand of Non-Invasive Cancer Diagnostics through systematic research, Analyze the competition pattern of Non-Invasive Cancer Diagnostics, so as to help solve the pain points of various stakeholders in Non-Invasive Cancer Diagnostics industry. This industry research report combines desktop research, qualitative interviews with insiders or experts and other methods to strive for the objectivity and integrity of conclusions and data.
Regional Segmentation (Value; Revenue, USD Million, 2018-2028) of Non-Invasive Cancer Diagnostics Market by XYZResearch Include
USA
Europe
China
Japan
India
Korea
Southeast Asia
Competitive Analysis; Who are the Major Players in Non-Invasive Cancer Diagnostics Market?
Gen-Probe Inc
Digene Corporation
Quest Diagnostics Inc
Cancer, Genetics Inc
BIOVIEW Inc
AVIVA Biosciences Corporation
Laboratory Corporation of America Holdings (LabCorp)
A&G Pharmaceutical
Affymetrix Inc
Precision Therapeutics
Major Type of Non-Invasive Cancer Diagnostics Covered in XYZResearch report:
CTCs
CTNAS
Exosomes
Application Segments Covered in XYZResearch Market
Blood
Urine
Saliva
For any other requirements, please feel free to contact us and we will provide you customized report.
| Report Attributes |
Report Details |
| Report Title |
(Post-pandemic Era)-Global Non-Invasive Cancer Diagnostics Market Segment Research Report 2022 |
| Historical Year |
2018 to 2022 (Data from 2010 can be provided as per availability) |
| Base Year |
2021 |
| Forecast Year |
2029 |
| Number of Pages |
102 Pages |
| Customization Available |
Yes, the report can be customized as per your need. |
TABLE OF CONTENTS
Table of Contents
Global Non-Invasive Cancer Diagnostics Market Segment Research Report 2022
1. Research Scope
2. Market Overview
2.1 Product Introduction, Application, Picture
2.2 Global Non-Invasive Cancer Diagnostics Market by Value
2.2.1 Global Non-Invasive Cancer Diagnostics Revenue by Type
2.2.2 Global Non-Invasive Cancer Diagnostics Market by Value (%)
2.3 Global Non-Invasive Cancer Diagnostics Market by Production
2.3.1 Global Non-Invasive Cancer Diagnostics Production by Type
2.3.2 Global Non-Invasive Cancer Diagnostics Market by Production (%)
3. The Major Driver of Non-Invasive Cancer Diagnostics Industry
3.1 Historical & Forecast Global Non-Invasive Cancer Diagnostics Demand
3.2 Largest Application for Non-Invasive Cancer Diagnostics (2018-2028)
3.3 The Major Downstream Company in China Market 2022
4. Global and Regional Non-Invasive Cancer Diagnostics Market
4.1 Regional Market Size in Terms of Production & Demand (2022)
4.2 Regional Market Share in Terms of Revenue (2018-2022)
4.3 Concentration Ratio (CR5& CR10) of Non-Invasive Cancer Diagnostics Market
4.4 Mergers & Acquisitions, Expansion Plans
5. US Non-Invasive Cancer Diagnostics Production, Demand (2018-2028)
5.1 Current and Estimated Production Breakdown by Type
5.2 Current and Estimated Demand Breakdown by Type
5.3 Current and Estimated Demand Breakdown by Application
5.4 Current and Estimated Revenue Breakdown by Type (2018-2028)
5.5 Current and Estimated Revenue Breakdown by Application (2018-2028)
6. Europe Non-Invasive Cancer Diagnostics Production, Demand (2018-2028)
6.1 Current and Estimated Production Breakdown by Type
6.2 Current and Estimated Demand Breakdown by Type
6.3 Current and Estimated Demand Breakdown by Application
6.4 Current and Estimated Revenue Breakdown by Type (2018-2028)
6.5 Current and Estimated Revenue Breakdown by Application (2018-2028)
7. China Non-Invasive Cancer Diagnostics Production, Demand (2018-2028)
7.1 Current and Estimated Production Breakdown by Type
7.2 Current and Estimated Demand Breakdown by Type
7.3 Current and Estimated Demand Breakdown by Application
7.4 Current and Estimated Revenue Breakdown by Type (2018-2028)
7.5 Current and Estimated Revenue Breakdown by Application (2018-2028)
8. Japan Non-Invasive Cancer Diagnostics Production, Demand (2018-2028)
8.1 Current and Estimated Production Breakdown by Type
8.2 Current and Estimated Demand Breakdown by Type
8.3 Current and Estimated Demand Breakdown by Application
8.4 Current and Estimated Revenue Breakdown by Type (2018-2028)
8.5 Current and Estimated Revenue Breakdown by Application (2018-2028)
9. India Non-Invasive Cancer Diagnostics Production, Demand (2018-2028)
9.1 Current and Estimated Production Breakdown by Type
9.2 Current and Estimated Demand Breakdown by Type
9.3 Current and Estimated Demand Breakdown by Application
9.4 Current and Estimated Revenue Breakdown by Type (2018-2028)
9.5 Current and Estimated Revenue Breakdown by Application (2018-2028)
10. Korea Non-Invasive Cancer Diagnostics Production, Demand (2018-2028)
10.1 Current and Estimated Production Breakdown by Type
10.2 Current and Estimated Demand Breakdown by Type
10.3 Current and Estimated Demand Breakdown by Application
10.4 Current and Estimated Revenue Breakdown by Type (2018-2028)
10.5 Current and Estimated Revenue Breakdown by Application (2018-2028)
11. Southeast Asia Non-Invasive Cancer Diagnostics Production, Demand (2018-2028)
11.1 Current and Estimated Production Breakdown by Type
11.2 Current and Estimated Demand Breakdown by Type
11.3 Current and Estimated Demand Breakdown by Application
11.4 Current and Estimated Revenue Breakdown by Type (2018-2028)
11.5 Current and Estimated Revenue Breakdown by Application (2018-2028)
12. Global Non-Invasive Cancer Diagnostics Average Price Trend
12.1 Market Price for Each Type of Non-Invasive Cancer Diagnostics in US (2018-2022)
12.2 Market Price for Each Type of Non-Invasive Cancer Diagnostics in Europe (2018-2022)
12.3 Market Price for Each Type of Non-Invasive Cancer Diagnostics in China (2018-2022)
12.4 Market Price for Each Type of Non-Invasive Cancer Diagnostics in Japan (2018-2022)
12.5 Market Price for Each Type of Non-Invasive Cancer Diagnostics in India (2018-2022)
12.6 Market Price for Each Type of Non-Invasive Cancer Diagnostics in Korea (2018-2022)
12.7 Market Price for Each Type of Non-Invasive Cancer Diagnostics in Southeast Asia (2018-2022)
13. Industrial Chain (Impact of COVID-19)
13.1 Non-Invasive Cancer Diagnostics Industrial Chain Analysis
13.2 Downstream
13.3 Impact of COVID-19
13.4 Post-pandemic Era
13.5 Technology Trends of Non-Invasive Cancer Diagnostics
14. Non-Invasive Cancer Diagnostics Competitive Landscape
14.1 Gen-Probe Inc
14.1.1 Gen-Probe Inc Company Profiles
14.1.2 Gen-Probe Inc Product Introduction
14.1.3 Gen-Probe Inc Non-Invasive Cancer Diagnostics Sales, Revenue (2018-2022)
14.1.4 Strategic initiatives
14.2 Digene Corporation
14.2.1 Digene Corporation Company Profiles
14.2.2 Digene Corporation Product Introduction
14.2.3 Digene Corporation Non-Invasive Cancer Diagnostics Sales, Revenue (2018-2022)
14.2.4 Strategic initiatives
14.3 Quest Diagnostics Inc
14.3.1 Quest Diagnostics Inc Company Profiles
14.3.2 Quest Diagnostics Inc Product Introduction
14.3.3 Quest Diagnostics Inc Non-Invasive Cancer Diagnostics Sales, Revenue (2018-2022)
14.3.4 Strategic initiatives
14.4 Cancer, Genetics Inc
14.4.1 Cancer, Genetics Inc Company Profiles
14.4.2 Cancer, Genetics Inc Product Introduction
14.4.3 Cancer, Genetics Inc Non-Invasive Cancer Diagnostics Sales, Revenue (2018-2022)
14.4.4 Strategic initiatives
14.5 BIOVIEW Inc
14.5.1 BIOVIEW Inc Company Profiles
14.5.2 BIOVIEW Inc Product Introduction
14.5.3 BIOVIEW Inc Non-Invasive Cancer Diagnostics Sales, Revenue (2018-2022)
14.5.4 Strategic initiatives
14.6 AVIVA Biosciences Corporation
14.6.1 AVIVA Biosciences Corporation Company Profiles
14.6.2 AVIVA Biosciences Corporation Product Introduction
14.6.3 AVIVA Biosciences Corporation Non-Invasive Cancer Diagnostics Sales, Revenue (2018-2022)
14.6.4 Strategic initiatives
14.7 Laboratory Corporation of America Holdings (LabCorp)
14.7.1 Laboratory Corporation of America Holdings (LabCorp) Company Profiles
14.7.2 Laboratory Corporation of America Holdings (LabCorp) Product Introduction
14.7.3 Laboratory Corporation of America Holdings (LabCorp) Non-Invasive Cancer Diagnostics Sales, Revenue (2018-2022)
14.7.4 Strategic initiatives
14.8 A&G Pharmaceutical
14.8.1 A&G Pharmaceutical Company Profiles
14.8.2 A&G Pharmaceutical Product Introduction
14.8.3 A&G Pharmaceutical Non-Invasive Cancer Diagnostics Sales, Revenue (2018-2022)
14.8.4 Strategic initiatives
14.9 Affymetrix Inc
14.9.1 Affymetrix Inc Company Profiles
14.9.2 Affymetrix Inc Product Introduction
14.9.3 Affymetrix Inc Non-Invasive Cancer Diagnostics Sales, Revenue (2018-2022)
14.9.4 Strategic initiatives
14.10 Precision Therapeutics
14.10.1 Precision Therapeutics Company Profiles
14.10.2 Precision Therapeutics Product Introduction
14.10.3 Precision Therapeutics Non-Invasive Cancer Diagnostics Sales, Revenue (2018-2022)
14.10.4 Strategic initiatives
15. Conclusion
16. Methodology and Data Source
LIST OF TABLES & FIGURES
List of Tables and Figures
Figure 1. Total Demand by Application of Non-Invasive Cancer Diagnostics Industry (Volume)
Figure 2. Non-Invasive Cancer Diagnostics Production & Demand by Regions in 2022
Figure 3. Regional Market Share in Terms of Revenue (2022&2027)
Figure 4. The Top 10 and 5 Players Market Share by Non-Invasive Cancer Diagnostics Revenue in 2022
Figure 5. US Non-Invasive Cancer Diagnostics Production, Demand (2018-2028)
Figure 6. Production Breakdown by Type (%)
Figure 7. Demand Breakdown by Type (%)
Figure 8. Demand Breakdown by Application (%)
Figure 9. Revenue Breakdown by Type (%)
Figure 10. Revenue Breakdown by Application (%)
Figure 11. Europe Non-Invasive Cancer Diagnostics Production, Demand (2018-2028)
Figure 12. Production Breakdown by Type (%)
Figure 13. Demand Breakdown by Type (%)
Figure 14. Demand Breakdown by Application (%)
Figure 15. Revenue Breakdown by Type (%)
Figure 16. Revenue Breakdown by Application (%)
Figure 17. China Non-Invasive Cancer Diagnostics Production, Demand (2018-2028)
Figure 18. Production Breakdown by Type (%)
Figure 19. Demand Breakdown by Type (%)
Figure 20. Demand Breakdown by Application (%)
Figure 21. Current and Estimated Revenue Breakdown by Type
Figure 22. Revenue Breakdown by Type (%)
Figure 23. Revenue Breakdown by Application (%)
Figure 24. Japan Non-Invasive Cancer Diagnostics Production, Demand (2018-2028)
Figure 25. Production Breakdown by Type (%)
Figure 26. Demand Breakdown by Type (%)
Figure 27. Demand Breakdown by Application (%)
Figure 28. Revenue Breakdown by Type (%)
Figure 29. Revenue Breakdown by Application (%)
Figure 30. India Non-Invasive Cancer Diagnostics Production, Demand (2018-2028)
Figure 31. Production Breakdown by Type (%)
Figure 32. Demand Breakdown by Type (%)
Figure 33. Demand Breakdown by Application (%)
Figure 34. Revenue Breakdown by Type (%)
Figure 35. Revenue Breakdown by Application (%)
Figure 36. Korea Non-Invasive Cancer Diagnostics Production, Demand (2018-2028)
Figure 37. Production Breakdown by Type (%)
Figure 38. Demand Breakdown by Type (%)
Figure 39. Demand Breakdown by Application (%)
Figure 40. Revenue Breakdown by Type (%)
Figure 41. Revenue Breakdown by Application (%)
Figure 42. Southeast Asia Non-Invasive Cancer Diagnostics Production, Demand (2018-2028)
Figure 43. Current and Estimated Production Breakdown by Type (2018-2028)
Figure 44. Production Breakdown by Type (%)
Figure 45. Demand Breakdown by Type (%)
Figure 46. Revenue Breakdown by Type (%)
Figure 47. Revenue Breakdown by Application (%)
Figure 48. Industrial Chain
Table 1. Top Manufacturers and Market Segmentation
Table 2. Product Introduction, Application, Picture
Table 3. Non-Invasive Cancer Diagnostics Revenue, by Type (Million USD) (2018-2028)
Table 4. Non-Invasive Cancer Diagnostics Production, by Type (K Unit) (2018-2028)
Table 5. Non-Invasive Cancer Diagnostics Demand (K Unit) by Application (2018-2028)
Table 6. Non-Invasive Cancer Diagnostics Demand (Million USD) by Application (2018-2028)
Table 7. The Major Downstream Company in China
Table 8. Regional Market Share in Terms of Production & Demand (2022)
Table 9. Regional Market Share in Terms of Revenue (2022&2027)
Table 10. Ranking of Global Top Non-Invasive Cancer Diagnostics Companies by Revenue, Concentration Ratio in 2022
Table 11. Mergers & Acquisitions, Expansion Plans
Table 12. US Non-Invasive Cancer Diagnostics Production (K Unit), Market Revenue (Million USD), Demand (K Unit) (2018-2028)
Table 13. Current and Estimated Production Breakdown by Type (2018-2028)
Table 14. Current and Estimated Demand Breakdown by Type (2018-2028)
Table 15. Current and Estimated Demand Breakdown by Application (2018-2028)
Table 16. Current and Estimated Revenue Breakdown by Type
Table 17. Current and Estimated Revenue Breakdown by Application
Table 18. Europe Non-Invasive Cancer Diagnostics Production (K Unit), Market Revenue (Million USD), Demand (K Unit) (2018-2028)
Table 19. Current and Estimated Production Breakdown by Type (2018-2028)
Table 20. Current and Estimated Demand Breakdown by Type (2018-2028)
Table 21. Current and Estimated Demand Breakdown by Application (2018-2028)
Table 22. Current and Estimated Revenue Breakdown by Type
Table 23. Current and Estimated Revenue Breakdown by Application
Table 24. China Non-Invasive Cancer Diagnostics Production (K Unit), Market Revenue (Million USD), Demand (K Unit) (2018-2028)
Table 25. Table Current and Estimated Production Breakdown by Type
Table 26. Current and Estimated Demand Breakdown by Type
Table 27. Current and Estimated Demand Breakdown by Application
Table 28. Current and Estimated Revenue Breakdown by Application
Table 29. Japan Non-Invasive Cancer Diagnostics Production (K Unit), Market Revenue (Million USD), Demand (K Unit) (2018-2028)
Table 30. Current and Estimated Production Breakdown by Type (2018-2028)
Table 31. Current and Estimated Demand Breakdown by Type (2018-2028)
Table 32. Current and Estimated Demand Breakdown by Application (2018-2028)
Table 33. Current and Estimated Revenue Breakdown by Type
Table 34. Current and Estimated Revenue Breakdown by Application
Table 35. India Non-Invasive Cancer Diagnostics Production (K Unit), Market Revenue (Million USD), Demand (K Unit) (2018-2028)
Table 36. Current and Estimated Production Breakdown by Type (2018-2028)
Table 37. Current and Estimated Demand Breakdown by Type (2018-2028)
Table 38. Current and Estimated Demand Breakdown by Application (2018-2028)
Table 39. Current and Estimated Revenue Breakdown by Type
Table 40. Current and Estimated Revenue Breakdown by Application
Table 41. Korea Non-Invasive Cancer Diagnostics Production (K Unit), Market Revenue (Million USD), Demand (K Unit) (2018-2028)
Table 42. Current and Estimated Production Breakdown by Type (2018-2028)
Table 43. Current and Estimated Demand Breakdown by Type (2018-2028)
Table 44. Current and Estimated Demand Breakdown by Application (2018-2028)
Table 45. Current and Estimated Revenue Breakdown by Type
Table 46. Current and Estimated Revenue Breakdown by Application
Table 47. Southeast Asia Non-Invasive Cancer Diagnostics Production (K Unit), Market Revenue (Million USD), Demand (K Unit) (2018-2028)
Table 48. Table Current and Estimated Demand Breakdown by Type (2018-2028)
Table 49. Current and Estimated Demand Breakdown by Application (2018-2028)
Table 50. Current and Estimated Revenue Breakdown by Type
Table 51. Current and Estimated Revenue Breakdown by Application
Table 52. Market Price (USD/Unit) for Each Type of Non-Invasive Cancer Diagnostics in US (2018-2022)
Table 53. Market Price (USD/Unit) for Each Type of Non-Invasive Cancer Diagnostics in Europe (2018-2022)
Table 54. Market Price (USD/Unit) for Each Type of Non-Invasive Cancer Diagnostics in China (2018-2022)
Table 55. Market Price (USD/Unit) for Each Type of Non-Invasive Cancer Diagnostics in Japan (2018-2022)
Table 56. Market Price (USD/Unit) for Each Type of Non-Invasive Cancer Diagnostics in India (2018-2022)
Table 57. Market Price (USD/Unit) for Each Type of Non-Invasive Cancer Diagnostics in Korea (2018-2022)
Table 58. Market Price (USD/Unit) for Each Type of Non-Invasive Cancer Diagnostics in Southeast Asia (2018-2022)
Table 59. Key Downstream Customer in Each Application Field
Table 60. Gen-Probe Inc Profiles
Table 61. Gen-Probe Inc Non-Invasive Cancer Diagnostics Product Introduction
Table 62. Gen-Probe Inc Non-Invasive Cancer Diagnostics Sales (Unit), Revenue (Million USD) (2018-2022)
Table 63. Gen-Probe Inc Strategic initiatives
Table 64. Digene Corporation Profiles
Table 65. Digene Corporation Non-Invasive Cancer Diagnostics Product Introduction
Table 66. Digene Corporation Non-Invasive Cancer Diagnostics Sales (Unit), Revenue (Million USD) (2018-2022)
Table 67. Digene Corporation Strategic initiatives
Table 68. Quest Diagnostics Inc Profiles
Table 69. Quest Diagnostics Inc Non-Invasive Cancer Diagnostics Product Introduction
Table 70. Quest Diagnostics Inc Non-Invasive Cancer Diagnostics Sales (Unit), Revenue (Million USD) (2018-2022)
Table 71. Quest Diagnostics Inc Strategic initiatives
Table 72. Cancer, Genetics Inc Profiles
Table 73. Cancer, Genetics Inc Non-Invasive Cancer Diagnostics Product Introduction
Table 74. Cancer, Genetics Inc Non-Invasive Cancer Diagnostics Sales (Unit), Revenue (Million USD) (2018-2022)
Table 75. Cancer, Genetics Inc Strategic initiatives
Table 76. BIOVIEW Inc Profiles
Table 77. BIOVIEW Inc Non-Invasive Cancer Diagnostics Product Introduction
Table 78. BIOVIEW Inc Non-Invasive Cancer Diagnostics Sales (Unit), Revenue (Million USD) (2018-2022)
Table 79. BIOVIEW Inc Strategic initiatives
Table 80. AVIVA Biosciences Corporation Profiles
Table 81. AVIVA Biosciences Corporation Non-Invasive Cancer Diagnostics Product Introduction
Table 82. AVIVA Biosciences Corporation Non-Invasive Cancer Diagnostics Sales (Unit), Revenue (Million USD) (2018-2022)
Table 83. AVIVA Biosciences Corporation Strategic initiatives
Table 84. Laboratory Corporation of America Holdings (LabCorp) Profiles
Table 85. Laboratory Corporation of America Holdings (LabCorp) Non-Invasive Cancer Diagnostics Product Introduction
Table 86. Laboratory Corporation of America Holdings (LabCorp) Non-Invasive Cancer Diagnostics Sales (Unit), Revenue (Million USD) (2018-2022)
Table 87. Laboratory Corporation of America Holdings (LabCorp) Strategic initiatives
Table 88. A&G Pharmaceutical Profiles
Table 89. A&G Pharmaceutical Non-Invasive Cancer Diagnostics Product Introduction
Table 90. A&G Pharmaceutical Non-Invasive Cancer Diagnostics Sales (Unit), Revenue (Million USD) (2018-2022)
Table 91. A&G Pharmaceutical Strategic initiatives
Table 92. Affymetrix Inc Profiles
Table 93. Affymetrix Inc Non-Invasive Cancer Diagnostics Product Introduction
Table 94. Affymetrix Inc Non-Invasive Cancer Diagnostics Sales (Unit), Revenue (Million USD) (2018-2022)
Table 95. Affymetrix Inc Strategic initiatives
Table 97. Precision Therapeutics Profiles
Table 98. Precision Therapeutics Non-Invasive Cancer Diagnostics Product Introduction
Table 99. Precision Therapeutics Non-Invasive Cancer Diagnostics Sales (Unit), Revenue (Million USD) (2018-2022)
Table 100. Precision Therapeutics Strategic initiatives
